Less than a tenth of individuals eligible to benefit from weight-loss injections like Wegovy are able to get them, warns the World Health Organization as it publishes its inaugural recommendations on the medications.
With in excess of 1,000,000,000 people worldwide currently classified as obese, it is urging increased and just access to this class of drugs.
Based on estimates, in excess of 2,000,000,000 are projected to be living with obesity by 2030 without intervention.
"The new guidance acknowledges that excess weight is a chronic disease that can be addressed with thorough and lifelong care," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are major barriers to universal availability to the treatments that can assist patients in reducing considerable weight, explains the organization.
Skinny Jab Supply Crisis
Even under the current most optimistic scenario, the production of such drugs would only suffice for around 100 million people – less than 10% of those who need them, as stated by the health organization.
The guideline encourages nations and manufacturers to increase access, through approaches including voluntary licensing.
A patent on the active ingredient – the core component of the drug Wegovy – is set to lapse in a number of nations in 2026.
The Way Weight-Loss Jabs Work
These medications imitate a natural hormone to delay gastric emptying, curb appetite and increase the sense of being full so users eat less.
Patients commonly begin shedding pounds in the initial weeks of beginning the regular doses.
Research indicates users may regain a significant portion within a year of halting the medication, because their usual food cravings come back.
Being carrying excess weight elevates your risk for contracting diseases, like diabetes, heart disease, brain attack, and some malignancies.
Excess weight impacts people in every country and was responsible for millions of fatalities worldwide in 2024, as per the health agency.
